AU2015342324B2 - Drug for inhibiting adipose cell differentiation and insulin resistance - Google Patents

Drug for inhibiting adipose cell differentiation and insulin resistance Download PDF

Info

Publication number
AU2015342324B2
AU2015342324B2 AU2015342324A AU2015342324A AU2015342324B2 AU 2015342324 B2 AU2015342324 B2 AU 2015342324B2 AU 2015342324 A AU2015342324 A AU 2015342324A AU 2015342324 A AU2015342324 A AU 2015342324A AU 2015342324 B2 AU2015342324 B2 AU 2015342324B2
Authority
AU
Australia
Prior art keywords
seq
peg
modified
group
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015342324A
Other languages
English (en)
Other versions
AU2015342324A1 (en
Inventor
Yan Fu
Hui Li
Xinan Lu
Yongzhang Luo
Hui Wang
Shunli ZHAN
Daifu ZHOU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tsinghua University
Protgen Ltd
Original Assignee
Tsinghua University
Protgen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tsinghua University, Protgen Ltd filed Critical Tsinghua University
Publication of AU2015342324A1 publication Critical patent/AU2015342324A1/en
Application granted granted Critical
Publication of AU2015342324B2 publication Critical patent/AU2015342324B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2015342324A 2014-11-03 2015-11-03 Drug for inhibiting adipose cell differentiation and insulin resistance Active AU2015342324B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201410610777 2014-11-03
CN201410610777.X 2014-11-03
CN201510021469.8 2015-01-15
CN201510021469 2015-01-15
PCT/CN2015/093726 WO2016070798A1 (zh) 2014-11-03 2015-11-03 一种抑制脂肪细胞分化和胰岛素耐受的药物

Publications (2)

Publication Number Publication Date
AU2015342324A1 AU2015342324A1 (en) 2017-06-29
AU2015342324B2 true AU2015342324B2 (en) 2021-08-19

Family

ID=55908589

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015342324A Active AU2015342324B2 (en) 2014-11-03 2015-11-03 Drug for inhibiting adipose cell differentiation and insulin resistance

Country Status (7)

Country Link
US (2) US20180015148A1 (cg-RX-API-DMAC7.html)
EP (1) EP3246043A4 (cg-RX-API-DMAC7.html)
JP (2) JP2018501195A (cg-RX-API-DMAC7.html)
CN (2) CN114558111A (cg-RX-API-DMAC7.html)
AU (1) AU2015342324B2 (cg-RX-API-DMAC7.html)
CA (1) CA3003760A1 (cg-RX-API-DMAC7.html)
WO (1) WO2016070798A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016127948A1 (zh) * 2015-02-13 2016-08-18 清华大学 一种重组蛋白质药物的分子设计
CN115721730B (zh) 2016-11-10 2025-03-14 北京普罗吉生物科技发展有限公司 聚乙二醇化血管内皮抑制素类似物及其应用
US10276161B2 (en) 2016-12-27 2019-04-30 Google Llc Contextual hotwords

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101596320A (zh) * 2006-01-20 2009-12-09 清华大学 一种治疗肿瘤的药物及其应用
WO2012130141A1 (zh) * 2011-03-28 2012-10-04 清华大学 一种增强靶细胞摄取治疗剂的方法和药物组合物
CN103703140A (zh) * 2011-03-30 2014-04-02 德克萨斯大学系统董事会 用于靶向哺乳动物中的脂肪细胞的方法和组合物
EP2754718A1 (en) * 2011-09-09 2014-07-16 Tsinghua University Vascular endothelial myostatin mutant that mutates at atp binding sites

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2307792C (en) * 1997-10-31 2007-06-26 Children's Medical Center Corporation Method for regulating size and growth of vascularized normal tissue
AU2002323543A1 (en) * 2001-09-07 2003-03-24 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides against placenta and adipose tissues
US7524811B2 (en) * 2003-08-29 2009-04-28 Children's Medical Center Corporation Anti-angiogenic peptides from the N-terminus of endostatin
CN103083681A (zh) * 2006-01-20 2013-05-08 清华大学 一种治疗肿瘤的药物及其应用
BRPI0819434A2 (pt) * 2007-11-08 2019-09-24 Univ Utah Res Found método de tratamento ou prevenção de doenças hepáticas e uso de antagonistas á angiogênese em condições de proliferação venosa anormal
CN101219206A (zh) * 2008-02-01 2008-07-16 山东先声麦得津生物制药有限公司 重组人血管内皮抑制素在制药中的应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101596320A (zh) * 2006-01-20 2009-12-09 清华大学 一种治疗肿瘤的药物及其应用
WO2012130141A1 (zh) * 2011-03-28 2012-10-04 清华大学 一种增强靶细胞摄取治疗剂的方法和药物组合物
CN103703140A (zh) * 2011-03-30 2014-04-02 德克萨斯大学系统董事会 用于靶向哺乳动物中的脂肪细胞的方法和组合物
EP2754718A1 (en) * 2011-09-09 2014-07-16 Tsinghua University Vascular endothelial myostatin mutant that mutates at atp binding sites

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Coulon, S., et al., "Angiogenesis in chronic liver disease and its complications," (2010). Liver international, pp146 - 162, DOI:10.1111/j.1478-3231.2010.02369.x *
HUI WANG ET AL, "Endostatin Prevents Dietary-Induced Obesity by Inhibiting Adipogenesis and Angiogenesis", DIABETES, US, (2015-01-20), vol. 64, no. 7, doi:10.2337/db14-0528, ISSN 0012-1797, pages 2442 - 2456 *
Rupnick, M., et al., "Adipose tissue mass can be regulated through the vasculature," (2002). PNAS (99) no 15, pp10730 - 10735. doi/10.1073/pnas. 162349799 *
VIRTUE S ET AL, "Adipose tissue expandability, lipotoxicity and the Metabolic Syndrome An allostatic perspective", BIOCHIMICA ET BIOPHYSICA ACTA (2010) vol. 1801, no. 3, doi:10.1016/J.BBALIP.2009.12.006, pages 338 - 349 *
Yihai Cao, "Angiogenesis modulates adipogenesis and obesity", The Journal of Clinical Investigation. (2007); vol 117(9): pages 2362-2368. https://doi.org/10.1172/JCI32239 *

Also Published As

Publication number Publication date
US20180015148A1 (en) 2018-01-18
WO2016070798A1 (zh) 2016-05-12
CA3003760A1 (en) 2016-05-12
CN107148277A (zh) 2017-09-08
CN114558111A (zh) 2022-05-31
EP3246043A4 (en) 2018-09-05
JP7227197B2 (ja) 2023-02-21
EP3246043A1 (en) 2017-11-22
EP3246043A9 (en) 2018-03-14
JP2020172546A (ja) 2020-10-22
CN107148277B (zh) 2022-03-22
AU2015342324A1 (en) 2017-06-29
JP2018501195A (ja) 2018-01-18
US20220409703A1 (en) 2022-12-29

Similar Documents

Publication Publication Date Title
US20220409703A1 (en) Drug for inhibiting adipose cell differentiation and insulin resistance
ES2831329T3 (es) Péptido que presenta unos efectos antidiabéticos y antiobesidad, y utilización del mismo
Ou et al. Extracellular vesicles derived from microRNA-150-5p-overexpressing mesenchymal stem cells protect rat hearts against ischemia/reperfusion
Liu et al. Down-regulation of myocardial infarction associated transcript 1 improves myocardial ischemia-reperfusion injury in aged diabetic rats by inhibition of activation of NF-κB signaling pathway
US9416196B2 (en) Composition for prophylaxis or treatment of vascular or cardiac valvular calcification comprising dipeptidyl peptidase-4 inhibitor
Xiao et al. Therapeutic effects of neuregulin-1 gene transduction in rats with myocardial infarction
CN111494605B (zh) Creg蛋白用于预防或治疗阿霉素心肌损伤的医药用途
WO2016197592A1 (zh) 一种长链非编码rna hnf1a-as1在制备治疗人体恶性实体瘤药物中的应用
Zhu et al. NCOA4 linked to endothelial cell ferritinophagy and ferroptosis: a key regulator aggravate aortic endothelial inflammation and atherosclerosis
Li et al. Suppression of the expression of hypoxia-inducible factor-1α by RNA interference alleviates hypoxia-induced pulmonary hypertension in adult rats
US11793862B2 (en) Pharmaceutical composition for treating non-alcoholic fatty liver, non-alcoholic steatohepatitis, or hepatic fibrosis using Ssu72 protein or a polynucleotide encoding the same
KR20240130829A (ko) 허혈/재관류 손상
CN112691193B (zh) 用于治疗扩张型心肌病的药物及筛选方法及用途
Yeh Cellular senescence and aging.
CN108004310A (zh) 肾素(原)受体(p)rr基因及其抑制剂的应用
Su et al. Molecular characterization of vascular endothelial growth factor b from spotted sea bass (Lateolabrax maculatus) and its potential roles in decreasing lipid deposition
JP2012502007A (ja) 強皮症の治療
EP3116516A1 (en) Inducing brown fat fate and function
CN119013405A (zh) 包含utr的核酸构建体及其应用
CN107961382B (zh) miR-1252在制备治疗特应性皮炎的药物中的应用
EP3275467A1 (en) Pharmaceutical compositions for the treatment of left ventricular hypertrophy and dysfunction associated to metabolic syndrome
CN120758566B (zh) 一种在心肌细胞中特异性过表达zer1的病毒载体的构建及在心衰治疗中的应用
CN120695189A (zh) Rab27b和/或miR-295-3p在预防和/或治疗射血分数保留型心衰中的应用
CN116904577A (zh) 一种Bdh1蛋白在糖尿病心脏保护中的应用及基因药物
CN116478995A (zh) 用于治疗糖尿病心肌病的小核酸分子

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)